logo-loader

Cynata Therapeutics announces trial in critical COVID-19 patients using their technology

Published: 09:03 15 May 2020 AEST

Cynata Therapeutics (ASX: CYP) COO Kilian Kelly joined Steve Darling from Proactive Vancouver with news the unique stem cell biotech company is beginning a trial in patients suffering from the effects of the coronavirus.

Kelly telling Proactive how their technology works and why this technology is quite different from other stem cell companies. Kelly also talked about some of the pre and current clinical results.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

13 hours, 19 minutes ago